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Abstract
Overweight and obesity may increase risk of disease progression in men with prostate cancer, but there have been few studies of weight loss
interventions in this patient group. In this study overweight or obese men treated for prostate cancer were randomised to a self-help diet and
activity intervention with telephone-based dietitian support or a wait-list mini-intervention group. The intervention group had an initial group
meeting, a supporting letter from their urological consultant, three telephone dietitian consultations at 4-week intervals, a pedometer and access
to web-based diet and physical activity resources. At 12 weeks, men in both groups were given digital scales for providing follow-up weight
measurements, and thewait-list group received amini-intervention of the supporting letter, a pedometer and access to theweb-based resources.
Sixty-twomen were randomised; fifty-four completed baseline and 12-week measurements, and fifty-one and twenty-seven providedmeasure-
ments at 6 and 12 months, respectively. In a repeated-measures model, mean difference in weight change between groups (wait-list mini-inter-
ventionminus intervention) at 12weekswas−2·13 (95%CI−3·44,−0·82) kg (P= 0·002). At 12months the corresponding valuewas−2·43 (95%
CI −4·50, −0·37) kg (P= 0·022). Mean difference in global quality of life score change between groups at 12 weeks was 12·3 (95 % CI 4·93, 19·7)
(P= 0·002); at 12 months there were no significant differences between groups. Results suggest the potential of self-help diet and physical
activity intervention with trained support for modest but sustained weight loss in this patient group.
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Prostate cancer is now the second-most common cancer in men
worldwide: an estimated 1·1 million men were diagnosed with
prostate cancer in 2012, accounting for 15 % of all cancers in
men(1). In the UK, the lifetime risk of a diagnosis of prostate
cancer for men is one in eight, with 47 151 new cases in 2015
and 11 631 deaths in 2016(2). Excess body weight has been asso-
ciated with an increased risk of diagnosis of more aggressive
forms of prostate cancer and of recurrence and prostate cancer
mortality(3–6), although a recent umbrella review of the evidence
suggests that these associations may be modest and the strength
of evidence is ‘suggestive’ rather than ‘convincing’(7). One study
found that weight gain following diagnosis was associated with
an increased rate of prostate cancer-specific mortality(8), sug-
gesting that weight loss in those with excess weight could have
beneficial outcomes, but to date there are no published studies
on the influence of intentional weight loss on prostate cancer
progression.
While weight loss can be achieved by energy restriction
alone, physical activity may bring other health benefits such
as reduced fatigue, increased muscle strength and improved
cardio-metabolic health. For men with prostate cancer who
receive androgen deprivation therapy, physical activity may
help to prevent the loss of lean tissue mass(9). One study of a
6-month diet and exercise intervention for men with prostate
cancer receiving androgen deprivation therapy found beneficial
effects on weight and fat mass as well as physical functioning(10)
but specific evidence-based physical activity guidelines for
cancer survivors are lacking(11). There is a lack of studies
Abbreviations: EORTC, European Organisation for Research and Treatment of Cancer; IQR, interquartile range; QoL, quality of life; UCAN, Urological Cancer.
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including physical activity combined with diet intervention for
weight loss in prostate cancer patients, despite the evidence
showing the additional benefits in terms of maintenance of lean
tissue mass and other health benefits. From a systematic review
of twenty randomised controlled trials of diet and exercise inter-
ventions in men treated for prostate cancer we concluded that
low-fat or low-energy diets could lead to weight loss but that
exercise could have other benefits such as improvement in qual-
ity of life (QoL)(12). This review revealed some gaps in the evi-
dence including a lack of information on weight change in the
trials of exercise and the optimumdesign of diet or exercise inter-
ventions which would encourage adherence in this group. Many
of the studies combining diet and prescribed exercise have
found poor retention and adherence rates, and a recent study
by Focht et al. suggested that a more personalised, self-directed
weight loss intervention in prostate cancer patients rather than
more supervised exercise and dietary advice showed promise
for promoting adherence to independent lifestyle behaviour
change(9). To be applicable at scale, interventions need to be
not only effective but also cost-effective, which supports the
investigation of self-help resources such as internet and
mobile-phone-delivered programmes. A systematic review of
twenty-three studies of self-help interventions for weight loss
found a mean difference in weight loss of 1·85 (95 % CI 0·83,
2·86) kg at 6 months in favour of the intervention group though
the difference was no longer significant at 12 months(13). The
same review found evidence of greater weight loss with more
interactive programmes but less weight loss on self-help pro-
grammes in more socio-economically disadvantaged groups.
The Reach Out to Enhance Wellness (RENEW) study of a
home-based diet and exercise intervention in overweight or
obese survivors of colorectal, breast and prostate cancer survi-
vors aged over 65 years in the USA found weight loss and pres-
ervation of physical function following the intervention(14). In
this paper, we report the results of a pilot randomised controlled
trial of a 12-week self-help diet and physical activity intervention
on body weight and QoL in overweight and obese men treated
for prostate cancer.
Methods
The Prostate CancerWeight Management (PRO-MAN) studywas
conducted in North-East Scotland between October 2013 and
April 2015. Recruitment was carried out through the
Urological Cancer (UCAN) database, which covers all urology
cancer patients in Grampian, Orkney and Shetland regions.
Intervention design
To tailor the intervention to the needs and preferences of men
with prostate cancer we carried out a questionnaire survey in
265 men. Thirty-four of these men also took part in focus group
discussions, with fourteenmen being accompanied by their part-
ners. The questionnaire results indicated that the majority (58 %)
would prefer to do exercise on their own rather than in a group,
with walking, cycling and swimming being considered suitable
forms of exercise for 79 , 35 and 25%ofmen respectively. For the
majority of respondents the partners carried out most of the food
purchasing (62 %) and preparation (66 %); in the focus group
discussions it emerged that these men and their partners would
like information on specific foods to eat or avoid and control of
appetite and portion size, ideally delivered in a one-to-one rather
than group setting (H Mohamad, PhD thesis, University of
Aberdeen).
Based on this information and literature which suggested that
support from a clinician can promote adherence to behaviour
change programmes(15) we designed a self-help intervention
package which included an initial group meeting, a letter of
recommendation from the hospital consultant, a pedometer,
telephone-based diet advice and access to online diet and physi-
cal activity resources. At the beginning of the 12-week pro-
gramme, there was a 1 h group session with the two dietitians
(H. M. and J. C.) to give an overview of the study including
the duration of the study and frequency of contact and a dem-
onstration of how to access the web-based self-help resources.
Three groups were held in the evening at the CLAN local cancer
support charity centre, and one group was held in the UCAN
centre at Aberdeen Royal Infirmary during the daytime. Each
participant was given a pedometer as a self-monitoring tool to
encourage walking according to his own personal goals and a
letter from their individual urological consultant to encourage
them to comply with dietary modification and to engage in regu-
lar physical activity. The letter included the link and password to
the web-based self-help resources in the UCAN website which
provided additional written resources on appropriate diet and
physical activity such as World Cancer Research Fund and other
advice sheets and recipes. All participants and their partners
where requested received their own username and password
to access the resources.
Within a week of baseline measurement, each participant
was contacted by one of the dietitians. A 24 h diet recall was
undertaken to facilitate discussion around current food and drink
intake and to allow the dietitian to give individually tailored
dietary advice. The advice related to energy reduction through
decreasing portion sizes, reducing high-energy, high-fat, high-
sugar foods, reducing alcohol and encouraging higher consump-
tion of fruits, vegetables and wholegrains. Physical activity
advice was based on individual capability and preferences,
based on the discussion and self-monitoring of walking from
the pedometer. Participants were asked to provide a pedometer
reading at the two follow-up telephone calls to guide the advice
provided.
At the end of the telephone call, each participant set personal
diet and activity goals for the following 4 weeks, in discussion
with the dietitian. A written summary of the goals set was sent
out by mail to each participant. Following the initial phone call,
two further calls were made at 4 and 8 weeks follow-up.
These calls reviewed the goals and re-set new goals if required.
The telephone calls were recorded and used to summarise the
goals set.
Participants
Recruitment was carried out between October and December
2013. Inclusion criteria were age 16 years or over, a diagnosis
of localised or locally advanced prostate cancer within the last
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36 months and overweight or obesity, which was defined as
BMI≥ 25 kg/m2. In men aged 70 years or over only those with
BMI≥ 30 kg/m2were included to avoid adverse effects of weight
loss on mortality reported in overweight adults in this age
group(16). Exclusion criteria were evidence of distant metastases
or current involvement with any weight management pro-
gramme or other research studies. Potentially eligible partici-
pants were selected from the UCAN database. As the UCAN
database did not contain information on BMI, menwhowere eli-
gible on the basis of age and clinical stage were sent a letter of
invitation to participate in the study and a reply slip which also
asked for self-reported height and weight. Those who met the
BMI inclusion criteria on the basis of self-reported height and
weight were invited to attend a baseline meeting at which height
and weight were measured by one of the dietitians. Those who
met the BMI criteria on the basis of measured height and weight
and who agreed to participate were randomised to either inter-
vention or wait-list mini-intervention group using a minimisation
programme based on age, time since diagnosis and BMI.
Intervention group
Men in the intervention group received all components of the
intervention described earlier. At 12 weeks, they attended indi-
vidual appointments with one of the dietitians in the UCAN
centre at which weight was measured.
Wait-list mini-intervention group
Men in the wait-list mini-intervention group were seen individu-
ally at the UCAN centre for measurement of baseline height and
weight. Theywere not given any instruction on diet and physical
activity at this point but were asked to attend a secondmeeting at
the UCAN centre at 12 weeks, at which point weight was
measured and they were provided with a pedometer, a recom-
mendation letter from their consultant and a password for the
web-based self-help resources.
Measurement of outcomes
The primary outcomes were differences between groups in
change in body weight at 12 weeks and 12 months, which
was measured to the nearest 0·1 kg using calibrated digital scales
(SECA,model 803). At baseline and 12weeks, themeasurements
weremade by one of the dietitians. At the 12 weekmeeting, each
participant was given a set of the same digital weighing scales
along with written instructions on how to take measurements
of weight at later time points. Around 6 and 12 months, a record
sheet for providing weight measurement was mailed to each
participant.
The secondary outcome was health-related QoL which was
measured at baseline, 12 weeks and 6 and 12 months using
the European Organisation for Research and Treatment of
Cancer (EORTC) QLQ-C30 for assessing the generic aspects of
QoL, together with EORTC QLQ-PR25 which is specific for pros-
tate cancer(17). The questionnaire was mailed to the participants
before the baseline and 12 week meetings and with the
follow-up weight record sheet at around 6 and 12 months
along with a FREEPOST envelope to return the completed
questionnaire. All of the scales and single-item measures were
linearly transformed to a 0–100 score using the scoring pro-
cedure described by Fayers et al.(18).
The feasibility and acceptability of the intervention were
assessed using a questionnaire and auto-generated data on
website use. The questionnaire collected information on partic-
ipants’ views of the setting, content and delivery of the interven-
tion, using a five-point response scale to statements from
strongly agree to strongly disagree, with an open text box at
the end for any other comments. Participants in the intervention
group completed this at the end of the 12 weeks and the wait-list
mini-intervention group at the 6 month follow-up. Website use
was tracked from baseline to 12 weeks for the intervention and
12 weeks to 6 months in the wait-list mini-intervention group.
Data analysis
Baseline characteristics were summarised as means and stan-
dard deviations or medians and interquartile ranges (IQR) in
each randomised group and overall. Analysis of the repeated
measures of weight and QoL up to 12 months was carried out
using SAS, version 9.3 (SAS Institute Inc.). A linear mixed model
with unstructured covariance matrix was fitted to assess fixed
effects of time, group and time × group, adjusting for BMI,
age at baseline and years since diagnosis. All tests were two-
tailed, and an α level of 0·05 was applied as the criterion for stat-
istical significance. Estimates of difference in weight change and
the 95 % CI are reported from the mixed model for each treat-
ment group (baseline to 12 weeks, baseline to 6 months and
baseline to 12 months). In addition the difference between
the treatment groups is presented. All men with baseline mea-
surement were included in the analysis as the mixed-model
approach allows for missing data as long as one observed out-
come (at any follow-up) is available. An intention-to-treat
analysis was conducted, with men included in the group as
randomised (n 54).
Statistical power
As sample size was limited by feasibility of recruitment, the min-
imal effect size was calculated. For weight change at 12 weeks
the minimal detectable difference between the two groups
(n 26 and n 28) with 90 % power at the 5 % significance level
was 2·24 kg (assuming SD= 2·49), and for weight change at
12 months the minimum detectable difference between the
two groups was 5·56 kg (assuming SD= 4·21, n 16 and n 11).
Ethical committee approval
The present study was conducted according to the guidelines
laid down in the Declaration of Helsinki, and all procedures
involving human subjects were approved by the North of
Scotland Research Ethics Service. The initial study protocol,
which included measurements up to 6 months, was approved
by the North of Scotland Research Ethics Service on 9 August
2013 (REC reference 12/NS/0126) and subsequently approved
by NHS R&D on 16 September 2013 (reference 2012ON019).
A study amendment to allow postal follow-up at 12 months
was approved by the North of Scotland Research Ethics
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Service on 20 February 2015. Written informed consent was
obtained from all subjects.
Trial registration
The study was registered in Current Controlled Trials;
registration number ISRCTN46025196, https://doi.org/10.1186/
ISRCTN46025196.
Results
Recruitment and retention
Of the 313 men on the UCAN database, 286 potentially suitable
participants were approached. Ninety-two (32 %) expressed an
interest in participation, 3 (1 %) declined participation and 191
(67 %) did not respond (Fig. 1). Of those who expressed an inter-
est in the study, twenty-nine were below the minimum BMI
according to their age group and one man decided not to con-
tinue due to lack of time. The remaining sixty-two men were
randomised to the intervention (n 31) and wait-list mini-inter-
vention (n 31) groups. Four men randomised to the intervention
group could not attend any of the group sessions, and another
man withdrew as he was scheduled to undergo prostatectomy,
leaving twenty-six men who attended for baseline measure-
ments. Three men randomised to wait-list mini-intervention
group were not willing to travel to the study location for baseline
data collection as they lived too far away, leaving twenty-eight
who attended for baseline measurements.
Assessed for eligibility (n 92)
Excluded (n 30)
BMI outwith range (n 29)
Decided not to continue (n 1)
Weight and QoL measured (n 24)
Discontinued intervention (n 2)
Lost to follow-up (n 0)
Weight and QoL measured (n 26)
Allocated to intervention group (n 31)
Received allocated intervention (n 26)
Did not receive allocated intervention (n 5)
Could not attend group meeting (n 4)
Scheduled for prostatectomy (n 1)
Weight and QoL measured (n 28)
Allocated to wait-list control group (n 31)
Received allocated intervention (n 28)
Did not receive allocated intervention (n 3)
Withdrew (unwilling to travel to
baseline meeting) (n 3)
Weight and QoL measured (n 27)
Discontinued intervention (n 1)
Lost to follow-up (n 0)
Randomised (n 62)
Weight and QoL measured (n 11)
Discontinued intervention (n 1)
Lost to follow-up (n 12)
Weight and QoL measured (n 16)
Discontinued intervention (n 3)
Lost to follow-up (n 8)
Screened prior to eligibility
assessment (n 286)
Excluded (n 194)
Declined invitation (n 3)
Did not respond (n 191)
Fig. 1. Consolidated Standards of Reporting Trials (CONSORT) diagram of study recruitment and retention. QoL, quality of life.
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Four group sessions were arranged for men in the interven-
tion group. The group sessions consisted of four to nine partic-
ipants; five partners also attended the groups. Following this
meeting, the dietitians telephoned participants at 1, 4 and
8 weeks. Two men in the intervention group withdrew; one
man changed his mind, and another man withdrew due to an
unrelated health problem (coronary artery bypass). Twenty-
one participants completed all three planned telephone calls;
three completed two out of three telephone calls due to work
commitments and being away from home.
Twenty-four of the twenty-six men in the intervention group
and all twenty-eight men in the wait-list mini-intervention group
completed the outcomemeasurements at 12 weeks. At 6 months
one participant from thewait-list mini-intervention group did not
complete the weight and QoL measures as he had undergone a
hip replacement. At 12 months, eleven men in the intervention
group and sixteen in the wait-list mini-intervention group pro-
vided data on their weight and completed QoL questionnaires.
Baseline characteristics
The age range of participants was from 48 to 81 years with a
mean of 65·5 (SD 5·6) years. Two-thirds were aged over 65 years.
With regard to time since prostate cancer diagnosis, most (70 %)
had been diagnosed for more than a year. Mean weight, height
and BMI were 88·9 kg, 1·73 m and 29·6 kg/m2, respectively
(Table 1). The groups were balanced at baseline.
QoL assessed by EORTC modules composed of functional
scales, symptom scales and a global health status scale. The
baseline median score for global QoL of the participants was
83·3 with the most high/good level of functioning in physical
functioning and the lowest level of functioning in sexual activity.
Change in weight
The mean weight change in the intervention group at 12 weeks
was −1·89 (95 % CI −2·85, −0·93) kg (P< 0·001) and in the wait-
list mini-intervention group it was 0·24 (95 % CI −0·65, 1·13) kg
(P= 0·592) which was significantly different from the interven-
tion group (P= 0·002) as shown in Table 2.
Fifty-one (twenty-four intervention and twenty-seven wait-
list mini-intervention) and twenty-seven (eleven intervention
and sixteen wait-list mini-intervention) men provided weight
measurements at 6 and 12 months, respectively. Both interven-
tion and wait-list mini-intervention groups lost a significant
amount of weight between baseline and 6 months, but there
was no significant difference in the change between baseline
and6months between intervention andwait-listmini-intervention.
At 12months the averageweight changewas−3·75 (95%CI−5·31,
−2·18) kg; P< 0·001 in the intervention group and −1·31 (95 % CI
−2·66, 0·03) kg; P= 0·055 in the wait-list mini-intervention group,
with a significantly greater change of on average −2·43 kg
(P= 0·022) in the intervention group.
Four of the eleven participants in the intervention group and
one of the sixteen participants in the wait-list mini-intervention
group achieved clinically important ≥5 % weight loss at the
12 month follow-up.
Change in quality of life
The average global QoL score significantly increased in the inter-
vention group and significantly decreased in the wait-list mini-
intervention group between baseline and 12 weeks. There
was no significant change in global QoL in either group at
6 or 12 months. At both 12 weeks and 6 months there was a sig-
nificant difference in the changes in global QoL scores between
the two groups because the intervention group’s scores
improved whereas the wait-list mini-intervention group’s scores
decreased from the baseline measurements (Table 3).
There was no significant change in the symptoms QoL scale
in either group at any of the time points. The functional QoL scale
significantly improved in the intervention group between base-
line and 12 weeks, but there was no change in the wait-list mini-
intervention group leading to a significant difference between
the groups at this time point. However, there was no significant
change in functional QoL in either group at 6 or 12 months.
Adverse events
No adverse events were reported during the intervention.
Table 1. Physical and socio-demographic characteristics of participants at baseline
(Mean values and standard deviations; medians and interquartile ranges (IQR))
Total (n 54) Intervention (n 26)
Wait-list mini-intervention
(n 28)
Characteristics Mean SD Mean SD Mean SD
Age (years) 65·5 5·6 65·5 4·7 65·4 6·4
Weight (kg) 88·9 11·7 89·6 11·8 88·2 11·8
Height (m) 1·73 0·07 1·73 0·07 1·73 0·07
BMI (kg/m2) 29·6 2·9 29·8 3·1 29·4 2·6
Global QoL score
Median 83·3 79·2 83·3
IQR 66·7, 91·7 66·7, 83·3 66·7, 97·9
Functional QoL score
Median 91·1 91·1 93·3
IQR 79·4, 97·8 81·1, 97·8 76·7, 97·8
Symptoms QoL score
Median 7·7 7·7 7·7
IQR 2·6, 16·0 2·6, 10·9 2·6, 21·8
QoL, quality of life.
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Website use
Fifteen (58 %) of the twenty-four participants in the intervention
group and thirteen (46 %) of the twenty-eight participants in the
wait-list mini-intervention group accessed the online resources
during the 12 weeks of monitoring. The median number of visits
to the website was 5·0 (IQR 3·0, 15·0) for the intervention group
and 8·0 (IQR 3·5, 15·5) for the wait-list mini-intervention. The
median time spent on the website was 7·7 (IQR 1·1, 49·7) min
for the intervention group and 18·0 (IQR 8·4, 31·2) min for the
wait-list mini-intervention group. There were no significant
differences between the groups in either the median number
of visits or in the time spent on the website.
Discussion
Research on weight management in men with prostate cancer is
relatively new, and despite many potential benefits of lifestyle
change in cancer survivors, this population is under-researched.
Given the mean age of the patients with prostate cancer, tailored
self-help programmes with low-intensity physical activity
deserve investigation, because many may have side effects of
treatments such as urinary incontinence aswell as co-morbidities
such as orthopaedic problems.
In the present study, we found relatively modest weight loss
of 1·89 kg at 12 weeks in the intervention group, but by
12 months, the mean weight loss had increased to 3·75 kg, while
Table 2. Estimates of weight change (kg) from linear mixed effects model, adjusted for baseline age, BMI and time since diagnosis
(Estimates and 95 % confidence intervals)
Estimate 95 % CI P
Mini-intervention: baseline to 12 weeks 0·24 −0·65, 1·13 0·592
Mini-intervention: baseline to 6 months −2·12 −3·44, −0·79 0·002
Mini-intervention: baseline to 12 months −1·31 −2·66, 0·03 0·055
Intervention: baseline to 12 weeks −1·89 −2·85, −0·93 <0·001
Intervention: baseline to 6 months −3·40 −4·81, −1·99 <0·001
Intervention: baseline to 12 months −3·75 −5·31, −2·18 <0·001
Difference at 12 weeks (mini-intervention − intervention) −2·13 −3·44, −0·82 0·002
Difference at 6 months (mini-intervention − intervention) −1·28 −3·22, 0·65 0·189
Difference at 12 months (mini-intervention − intervention) −2·43 −4·50, −0·37 0·022
Table 3. Estimates of change in quality of life from linear mixed effects model, adjusted for baseline age, BMI and time since diagnosis
(Estimates and 95 % confidence intervals)
Estimate 95 % CI P
Global
Mini-intervention: baseline to 12 weeks −5·06 −10·1, −0·02 0·049
Mini-intervention: baseline to 6 months −5·14 −10·5, 0·26 0·062
Mini-intervention: baseline to 12 months −0·98 −7·00, 5·04 0·742
Intervention: baseline to 12 weeks 7·23 −1·86, 12·6 0·009
Intervention: baseline to 6 months 4·29 −1·42, 10·0 0·137
Intervention: baseline to 12 months −0·77 −7·61, 6·07 0·821
Difference at 12 weeks (mini-intervention − intervention) 12·3 4·93, 19·7 0·002
Difference at 6 months (mini-intervention − intervention) 9·43 1·57, 17·3 0·020
Difference at 12 months (mini-intervention − intervention) 0·22 −8·89, 9·33 0·962
Functional
Mini-intervention: baseline to 12 weeks −1·27 −4·55, 2·01 0·440
Mini-intervention: baseline to 6 months −1·72 −5·51, 2·07 0·367
Mini-intervention: baseline to 12 months 2·08 −0·99, 5·16 0·177
Intervention: baseline to 12 weeks 3·97 0·44, 7·50 0·028
Intervention: baseline to 6 months −0·21 −4·25, 3·83 0·916
Intervention: baseline to 12 months 2·65 −0·85, 6·14 0·133
Difference at 12 weeks (mini-intervention − intervention) 5·24 0·42, 10·1 0·033
Difference at 6 months (mini-intervention − intervention) 1·50 −4·03, 7·04 0·588
Difference at 12 months (mini-intervention − intervention) 0·56 −4·08, 5·21 0·807
Symptoms
Mini-intervention: baseline to 12 weeks 0·73 −1·11, 2·57 0·429
Mini-intervention: baseline to 6 months 1·00 −1·38, 3·39 0·399
Mini-intervention: baseline to 12 months −2·46 −5·60, 0·67 0·118
Intervention: baseline to 12 weeks −0·83 −2·83, 1·16 0·404
Intervention: baseline to 6 months −0·03 −2·55, 2·50 0·983
Intervention: baseline to 12 months −1·36 −4·93, 2·22 0·444
Difference at 12 weeks (mini-intervention − intervention) −1·57 −4·28, 1·15 0·252
Difference at 6 months (mini-intervention − intervention) −1·03 −4·50, 2·44 0·552
Difference at 12 months (mini-intervention − intervention) 1·11 −3·64, 5·85 0·637
Weight loss in men with prostate cancer 597
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in the mini-intervention group mean weight loss at 12 months
was 1·31 kg. Two other community-based weight loss trials
involving men in the UK reported fairly similar results. The
Lighten Up trial in overweight and obese men and women
recruited through primary care used eight different 12-week pro-
grammes and found a range of mean weight loss (either objec-
tively measured by the programme providers or researchers, or
self-reported (40 %)) from 1·37 to 4·43 kg at 12 weeks and 1·13 to
4·45 kg at 12 months, with greatest weight loss seen with com-
mercial weight loss programmes(19). The proportion of partici-
pants in each arm of the Lighten Up trial who achieved 5 %
weight loss at 12 months ranged from 14 to 31 %, comparable
with 36 % of the intervention arm participants in our study.
The 12-week Football Fans in Training (FFIT) intervention in
overweight and obese male football supporters in Scotland
achieved greater weight loss of on average 5·80 kg at 12 weeks
and 5·56 kg at 1 year(20), but the intervention was more intensive
as it involvedweekly group exercise and lifestyle sessions lasting
90 min, and weight was measured by the researchers. However,
the proportion of participants who achieved 5 % weight loss in
the intervention arm was 39 %, comparable with 36 % of the
intervention arm in our study. These interventions were more
intensive than that used in the present study: a better comparison
is with data from a lifestyle intervention with motivational inter-
viewing, telephone counselling and weighing scales in over-
weight and obese patients with colorectal adenoma in
Scotland which reported weight loss measured by the research-
ers of 3·50 kg in the intervention group and a difference of
2·69 kg between intervention and control groups at 12
months(21), similar to the corresponding values of 3·75 and
2·43 kg, respectively, in the present study. The proportion of
those in the intervention group who achieved 5 % weight loss
was 36 % which was the same as in our study. The US-based
RENEWstudy of self-directedweightmanagement in overweight
and obese survivors of breast, colorectal and prostate cancer,
which involved mailed self-help materials and telephone coun-
selling, reported a (self-reported) weight loss of approximately
2·46 kg in the intervention arms and 1·46 kg in the delayed inter-
vention arms over the relevant 12month intervention periods(14).
In the present study, we found few consistent differences in
QoL over the study. Thismay be a true finding or could reflect the
fact that the EORTC questionnaire is more suited to patients
undergoing active treatment than those who have largely recov-
ered from any side effects of treatment and can leadmore normal
lives. Alternative measures of well-being could be explored in
future studies.
A strength of the PRO-MAN intervention was the incorpora-
tion of the preferences of men treated for prostate cancer. The
fact that walking was a realistic physical activity for the majority
probably contributed to the popularity of the pedometers which
allowed goal-setting and self-monitoring and may have
increased adherence compared with higher intensity or gym-
based exercise. Pedometers were also found to be popular
and motivational for many participants in the Football Fans in
Training trial(22). Although men and their partners requested
advice on specific foods to include or avoid, the fact that the tele-
phone consultations and materials were able to focus on energy
intake control and general healthy eating could indicate that
reassurance that ‘superfoods’ were not specifically required
for secondary prevention of cancer may have been helpful.
Another strength of the studywas the low cost of the interven-
tion package: the cost of the pedometer, dietitians’ time and
travel to the group meeting in the intervention group was
approximately £90 per patient (€103). The provision of weighing
scales added approximately £30 (€34) per person to these costs:
although the scales were provided for provision of weight data, it
cannot be ruled out that they contributed to the longer-term
results in both groups. The most expensive component of the
intervention was the dietetic input for the initial group meeting
and telephone support, but the superiority of the 12-month
results in the intervention group suggests that thismay have been
important for sustained effects, consistent with the conclusions
of a systematic review(13). The least expensive components of
the intervention were the consultant’s letter and the web-based
materials. Website usage data showed that the internet-based
resources were not accessed frequently by the majority of par-
ticipants, though this may have been because the materials were
downloaded and subsequently used in print form.
The study also had some significant limitations. Only 32 %
of those invited to participate agreed to do so, though the lack
of recent weight data for the men on the UCAN database meant
that we could not exclude those who were not above the BMI
cut-offs in the initial mailing and do not know how many men
believed themselves to be normal weight and may not have
responded to the invitation letter for this reason. Future studies
should consider ways to obtain pre-recruitment weight and to
tackle other factors which could contribute to low recruitment
such as time and travel burden. The Grampian region has low
population density beyond the city of Aberdeen, so providing
groupmeetings at a wider range of locations and collecting fol-
low-up data for example in general practice clinics could be
considered. The fact that the wait-list mini-intervention group
received a sub-set of the intervention package and were given
this at 12 weeks makes it more difficult to compare results at
6 months, though at 12 months both groups had had no
face-to-face or telephone contact since 12 weeks so the results
at 12 months can be used to compare the different intervention
packages. However, the 12 month results should be inter-
preted with caution as only twenty-seven men recorded data
at 12 months, raising the possibility of selective loss to follow-
up of those who had not lost weight subsequently overestimat-
ing the weight loss. The retention was much higher at 6 months
which may reflect the fact that the 12-month follow-up was not
part of the original protocol. Although we provided accurate
scales and clear instructions for weighing to participants ensur-
ing consistency of equipment and its use, the use of self-
recorded weight measurements at 6 and 12 months raises
the possibility of reporting bias due to social desirability or
demand characteristics, as participants may report lower
weights leading to an overestimate of the weight loss.
However, Demark-Wahnefried et al.(23) found high levels of
agreement between self-reported and clinically assessed
BMI in cancer survivors aged 65 years and over and Jolly
et al.(19) found that those who self-reported their weight had
a smaller weight loss than those whose weight was objectively
measured and therefore this did not appear to be
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overestimating weight loss. In addition, we did not record the
energy intake or pedometer readings of participants; however,
this may have changed the nature of and the response to the
intervention by adding more self-monitoring. The study
included all men with a diagnosis of localised or locally
advanced prostate cancer within the past 36 months: we did
not limit inclusion by stage or type of treatment but also did
not record additional details about cancer stage, grade and
treatments, and therefore apart from time since diagnosis
we were unable to take clinical details into account in the
analysis. Lack of these details, in particular of those taking
hormonal therapy or who changed treatments over the course
of the study, may have affected the outcomes as androgen
deprivation therapy is known to affect body composition with
increases in weight and body fat in parallel with decreases in
muscle mass(9). Conversely, active treatment of another form
or cancer progression may have induced weight loss. In addi-
tion to affecting weight, QoL outcomes may have been influ-
enced by treatment side effects or cancer progression. Finally,
the measurement of outcome data and the statistical analysis
was not blind to the allocation of participants. Future studies
could consider alternative designs and outcome measures to
overcome these issues.
The results suggest the potential of a self-help diet and physi-
cal activity intervention with trained support for modest but sus-
tained weight loss in this patient group.
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